Delivery Order SPE2DB22D9239-SPE2DB26FDD64
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,347.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, issued on September 28, 2025, falls under the DLA's larger Pharmaceutical Prime Vendor Fleet program and represents a continuation of the agency's pharmaceutical supply chain operations. The contract carries no set-aside designation, reflecting DMS...
- The Defense Logistics Agency, operating under the Medical Supply Chain division, awarded a delivery order valued at $15,143.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, issued on October 14, 2025, with completion targeted for October 15, 2025, represents a discrete fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The award carries no...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $3,323.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group Inc. under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The IDC enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,030.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on September 17, 2025, represents a firm fixed-price purchase under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. The contract required no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $1,562.31 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This firm fixed-price delivery order, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, represents one of numerous awards made to DMS Pharmaceutical Group under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V)...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $24,293.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on October 17, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,534.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on August 3, 2025. This delivery order, designated as a Pharm Prime Vendor Fleet contract, carries a firm fixed-price structure with an ultimate completion date of August 4, 2025. The award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete directly in the federal...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $4,910.07 to DMS Pharmaceutical Group Inc. for SYFOVRE 15 mg/0.1 mL vials on September 26, 2025, with completion targeted for October 20, 2025. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will provide this pharmaceutical product under a firm fixed-price delivery order arrangement with no set-aside designation. The company leverages its...
- The Defense Logistics Agency, through its Medical Supply Chain division, awarded a delivery order valued at $6,502.99 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, issued on June 2, 2025 with an ultimate completion date of June 6, 2025, represents a discrete purchase under the vendor's larger Indefinite Delivery Contract with the DLA. DMS Pharmaceutical Group holds a significant...
- The Defense Logistics Agency issued a delivery order valued at $17,267.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, awarded on August 26, 2025, is designated as a Pharma Prime Vendor Fleet contract and carries an ultimate completion date of August 27, 2025. The award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete on its merits within the open...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB26FDD64Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,546.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of SYFOVRE 15 mg/0.1 mL vials. The award, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, utilizes firm fixed-price pricing and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group Inc. serves as one of multiple regional prime vendor contractors under the PPV-G GEN V program, which authorizes DLA to issue firm fixed-price delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, and medical consumables. The company's parent IDC, designated SPE2DR and awarded November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods. This delivery order represents one of numerous awards issued to the contractor by DLA's Medical Supply Chain division, reflecting the company's established performance in supplying critical pharmaceutical products to support military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.5k | 10/16/25 |